Page 1610 - Williams Hematology ( PDFDrive )

1584 Part XI: Malignant Lymphoid Diseases Chapter 95: General Considerations for Lymphomas 1585

115. Perlman S, Becker-Catania S, Gatti RA: Ataxia-telangiectasia: Diagnosis and treatment. 148. Merlin E, Chabrier S, Verkarre V, et al: Primary leptomeningeal ALK+ lymphoma in a
Semin Pediatr Neurol 10:173–182, 2003. 13-year-old child. J Pediatr Hematol Oncol 30:963–967, 2008.
116. Rangel-Santos A, Wakim VL, Jacob CM, et al: Molecular characterization of patients 149. Nayak L, Batchelor TT: Recent advances in treatment of primary central nervous
with X-linked Hyper-IgM syndrome: Description of two novel CD40L mutations. system lymphoma. Curr Treat Options Oncol 14:539–552, 2013.
Scand J Immunol 69:169–173, 2009. 150. Korfel A, Schlegel U: Diagnosis and treatment of primary CNS lymphoma. Nat Rev
117. Rengan R, Ochs HD: Molecular biology of the Wiskott-Aldrich syndrome. Rev Immu- Neurol 9:317–327, 2013.
nogenet 2:243–255, 2000. 151. Ferreri AJ: How I treat primary CNS lymphoma. Blood 118:510–522, 2011.
118. Sackey K, Odone V, George SL, et al: Poland’s syndrome associated with childhood 152. Epelbaum R, Haim N, Ben-Shahar M, et al: Non-Hodgkin’s lymphoma presenting with
non-Hodgkin’s lymphoma. Am J Dis Child 138:600–601, 1984. spinal epidural involvement. Cancer 58:2120–2124, 1986.
119. Shcherbina A, Candotti F, Rosen FS, et al: High incidence of lymphomas in a subgroup 153. Paul T, Challa S, Tandon A, et al: Primary central nervous system lymphomas: Indian
of Wiskott-Aldrich syndrome patients. Br J Haematol 121:529–530, 2003. experience, and review of literature. Indian J Cancer 45:112–118, 2008.
120. Srivastava S, Zou ZQ, Pirollo K, et al: Germ-line transmission of a mutated p53 gene in 154. Kozakova D, Machalekova K, Brtko P, et al: Primary B-cell pituitary lymphoma of the
a cancer-prone family with Li-Fraumeni syndrome. Nature 348:747–749, 1990. Burkitt type: Case report of the rare clinic entity with typical clinical presentation. Cas
121. Cohen BJ, Moskowitz C, Straus D, et al: Cyclophosphamide/fludarabine (CF) is active Lek Cesk 147:569–573, 2008.
in the treatment of mantle cell lymphoma. Leuk Lymphoma 42:1015–1022, 2001. 155. Layden BT, Dubner S, Toft DJ, et al: Primary CNS lymphoma with bilateral symmet-
122. Vergin C, Cetingul N, Kavakli K, et al: A patient with WT syndrome and Castleman ric hypothalamic lesions presenting with panhypopituitarism and diabetes insipidus.
disease. Acta Paediatr Jpn 37:108–112, 1995. Pituitary 14:194–197, 2011.
123. Winkelstein JA, Marino MC, Ochs H, et al: The X-linked hyper-IgM syndrome: Clinical 156. Moshkin O, Muller P, Scheithauer BW, et al: Primary pituitary lymphoma: A histo-
and immunologic features of 79 patients. Medicine (Baltimore) 82:373–384, 2003. logical, immunohistochemical, and ultrastructural study with literature review. Endocr
124. Dunleavy K, Wilson WH: How I treat HIV-associated lymphoma. Blood 119: Pathol 20:46–49, 2009.
3245–3255, 2012. 157. Woolf DK, Ahmed M, Plowman PN: Primary lymphoma of the ocular adnexa (orbital
125. Capello D, Rossi D, Gaidano G: Post-transplant lymphoproliferative disorders: Molec- lymphoma) and primary intraocular lymphoma. Clin Oncol (R Coll Radiol) 24:
ular basis of disease histogenesis and pathogenesis. Hematol Oncol 23:61–67, 2005. 339–344, 2012.
126. Dolcetti R: B lymphocytes and Epstein-Barr virus: The lesson of post-transplant lymp- 158. Riemens A, Bromberg J, Touitou V, et al: Treatment strategies in primary vitreoretinal
hoproliferative disorders. Autoimmun Rev 7:96–101, 2007. lymphoma: A 17-center European collaborative study. JAMA Ophthalmol 133:191–197,
127. Taylor AL, Marcus R, Bradley JA: Post-transplant lymphoproliferative disorders 2014.
(PTLD) after solid organ transplantation. Crit Rev Oncol Hematol 56:155–167, 2005. 159. Munch-Petersen HD, Rasmussen PK, Coupland SE, et al: Ocular adnexal diffuse large
128. Jamali FR, Otrock ZK, Soweid AM, et al: An overview of the pathogenesis and natural B-cell lymphoma: A multicenter international study. JAMA Ophthalmol 133:165–173,
history of post-transplant T-cell lymphoma (corrected and republished article origi- 2015.
nally printed in Leukemia & Lymphoma, June 2007; 48(6): 1237–1241). Leuk Lymphoma 160. Sjo LD: Ophthalmic lymphoma: Epidemiology and pathogenesis. Acta Ophthalmol 87
48:1780–1784, 2007. Thesis 1:1–20, 2009.
129. Lok C, Viseux V, Denoeux JP, et al: Post-transplant cutaneous T-cell lymphomas. Crit 161. Sjo LD, Ralfkiaer E, Prause JU, et al: Increasing incidence of ophthalmic lymphoma in
Rev Oncol Hematol 56:137–145, 2005. Denmark from 1980 to 2005. Invest Ophthalmol Vis Sci 49:3283–3288, 2008.
130. Ekstrom Smedby K, Vajdic CM, Falster M, et al: Autoimmune disorders and risk of non 162. Corradini P, Marchetti M, Barosi G, et al: SIE-SIES-GITMO Guidelines for the man-
-Hodgkin lymphoma subtypes: A pooled analysis within the InterLymph Consortium. agement of adult peripheral T- and NK-cell lymphomas, excluding mature T-cell leu-
Blood 111:4029–4038, 2008. kaemias. Ann Oncol 25:2339–2350, 2014.
131. Troch M, Woehrer S, Streubel B, et al: Chronic autoimmune thyroiditis (Hashimoto’s 163. Au WY, Weisenburger DD, Intragumtornchai T, et al: Clinical differences between
thyroiditis) in patients with MALT lymphoma. Ann Oncol 19:1336–1339, 2008. nasal and extranasal natural killer/T-cell lymphoma: A study of 136 cases from the
132. Ji J, Shu X, Li X, et al: Cancer risk in hospitalized sarcoidosis patients: A follow-up study International Peripheral T-Cell Lymphoma Project. Blood 113:3931–3937, 2009.
in Sweden. Ann Oncol 20:1121–1126, 2009. 164. Schmitz N, Trumper L, Ziepert M, et al: Treatment and prognosis of mature T-cell
133. Brassesco MS: Leukemia/lymphoma-associated gene fusions in normal individuals. and NK-cell lymphoma: An analysis of patients with T-cell lymphoma treated in stud-
Genet Mol Res 7:782–790, 2008. ies of the German High-Grade Non-Hodgkin Lymphoma Study Group. Blood 116:
134. Ong ST, Le Beau MM: Chromosomal abnormalities and molecular genetics of non- 3418–3425, 2010.
Hodgkin’s lymphoma. Semin Oncol 25:447–460, 1998. 165. Kim GE, Koom WS, Yang WI, et al: Clinical relevance of three subtypes of primary
135. Korsmeyer SJ: Bcl-2 initiates a new category of oncogenes: Regulators of cell death. sinonasal lymphoma characterized by immunophenotypic analysis. Head Neck 26:
Blood 80:879–886, 1992. 584–593, 2004.
136. Hockenbery DM, Zutter M, Hickey W, et al: BCL2 protein is topographically restricted 166. Oprea C, Cainap C, Azoulay R, et al: Primary diffuse large B-cell non-Hodgkin
in tissues characterized by apoptotic cell death. Proc Natl Acad Sci U S A 88:6961–6965, lymphoma of the paranasal sinuses: A report of 14 cases. Br J Haematol 131:468–471,
1991. 2005.
137. Neri A, Barriga F, Knowles DM, et al: Different regions of the immunoglobulin heavy- 167. Mathews Griner LA, Guha R, Shinn P, et al: High-throughput combinatorial screening
chain locus are involved in chromosomal translocations in distinct pathogenetic forms identifies drugs that cooperate with ibrutinib to kill activated B-cell-like diffuse large
of Burkitt lymphoma. Proc Natl Acad Sci U S A 85:2748–2752, 1988. B-cell lymphoma cells. Proc Natl Acad Sci U S A 111:2349–2354, 2014.
138. Ballerini P, Gaidano G, Gong JZ, et al: Multiple genetic lesions in acquired immunode- 168. Shohat I, Berkowicz M, Dori S, et al: Primary non-Hodgkin’s lymphoma of the sinona-
ficiency syndrome-related non-Hodgkin’s lymphoma. Blood 81:166–176, 1993. sal tract. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 97:328–331, 2004.
139. Hamilton-Dutoit SJ, Pallesen G, Franzmann MB, et al: AIDS-related lymphoma. 169. Yamaguchi M, Suzuki R, Kwong YL, et al: Phase I study of dexamethasone, methotrex-
Histopathology, immunophenotype, and association with Epstein-Barr virus as ate, ifosfamide, L-asparaginase, and etoposide (SMILE) chemotherapy for advanced-
demonstrated by in situ nucleic acid hybridization. Am J Pathol 138:149–163, 1991. stage, relapsed or refractory extranodal natural killer (NK)/T-cell lymphoma and
140. Filippa DA, Ladanyi M, Wollner N, et al: CD30 (Ki-1)-positive malignant lymphomas: leukemia. Cancer Sci 99:1016–1020, 2008.
Clinical, immunophenotypic, histologic, and genetic characteristics and differences 170. Lee GW, Go SI, Kim SH, et al: Clinical outcome and prognosis of patients with
with Hodgkin’s disease. Blood 87:2905–2917, 1996. primary sinonasal tract diffuse large B-cell lymphoma treated with rituximab-
141. Morris SW, Kirstein MN, Valentine MB, et al: Fusion of a kinase gene, ALK, to a nucle- cyclophosphamide, doxorubicin, vincristine and prednisone chemotherapy: A study
olar protein gene, NPM, in non-Hodgkin’s lymphoma. Science 263:1281–1284, 1994. by the Consortium for Improving Survival of Lymphoma. Leuk Lymphoma 1–7, 2014.
142. Downing JR, Shurtleff SA, Zielenska M, et al: Molecular detection of the (2;5) translo- [Epub ahead of print]
cation of non-Hodgkin’s lymphoma by reverse transcriptase-polymerase chain reac- 171. Willemze R, Dreyling M: Primary cutaneous lymphoma: ESMO clinical recommenda-
tion. Blood 85:3416–3422, 1995. tions for diagnosis, treatment and follow-up. Ann Oncol 20 Suppl 4:115–118, 2009.
143. Lopategui JR, Sun LH, Chan JK, et al: Low frequency association of the t(2;5) 172. Levy A, Randall MB, Henson T: Primary cutaneous B-cell lymphoma, leg type restricted
(p23;q35) chromosomal translocation with CD30+ lymphomas from American and to the subcutaneous fat arising in a patient with dermatomyositis. Am J Dermatopathol
Asian patients. A reverse transcriptase-polymerase chain reaction study. Am J Pathol 30:578–581, 2008.
146:323–328, 1995. 173. Zhao J, Han B, Shen T, et al: Primary cutaneous diffuse large B-cell lymphoma (leg type)
144. DeCoteau JF, Butmarc JR, Kinney MC, et al: The t(2;5) chromosomal translocation is after renal allograft: Case report and review of the literature. Int J Hematol 89:113–117,
not a common feature of primary cutaneous CD30+ lymphoproliferative disorders: 2009.
Comparison with anaplastic large-cell lymphoma of nodal origin. Blood 87:3437–3441, 174. Hu YH, Hsiao LT, Yang CF, et al: Prognostic factors of Chinese patients with primary
1996. pulmonary non-Hodgkin’s lymphoma: The single-institute experience in Taiwan. Ann
145. Campbell LJ: Cytogenetics of lymphomas. Pathology 37:493–507, 2005. Hematol 88:839–846, 2009.
146. Press OW, Unger JM, Rimsza LM, et al: A comparative analysis of prognostic factor 175. Kennedy JL, Nathwani BN, Burke JS, et al: Pulmonary lymphomas and other pulmo-
models for follicular lymphoma based on a phase III trial of CHOP-rituximab versus nary lymphoid lesions. A clinicopathologic and immunologic study of 64 patients.
CHOP + 131iodine–tositumomab. Clin Cancer Res 19:6624–6632, 2013. Cancer 56:539–552, 1985.
147. Campbell JJ, Clark RA, Watanabe R, et al: Sézary syndrome and mycosis fungoides arise 176. Tabatabai A, Hashemi M, Ahmadinejad M, et al: Primary chest wall lymphoma with no
from distinct T-cell subsets: A biologic rationale for their distinct clinical behaviors. history of tuberculous pyothorax: Diagnosis and treatment. J Thorac Cardiovasc Surg
Blood 116:767–771, 2010. 136:1472–1475, 2008.

Kaushansky_chapter 95_p1569-1586.indd 1585 9/21/15 12:17 PM